41003-10-5

Usage

Uses

Used in Pharmaceutical Industry:
Glycine Bisphosphonate HBr is used as a pharmaceutical agent for its potential role in treating various bone-related disorders. Its ability to chelate metal ions and inhibit specific enzymes can be utilized in the development of drugs targeting bone metabolism and resorption.
Used in Agricultural Industry:
Glycine Bisphosphonate HBr is used as an inhibitor of the plant vacuolar proton-pumping pyrophosphatase. This application can help in understanding the role of this enzyme in plant physiology and potentially lead to the development of new strategies for crop improvement or protection against certain plant diseases.
Used in Chemical Research:
As a bisphosphonate derivative, Glycine Bisphosphonate HBr can be used in chemical research to study the properties and reactivity of bisphosphonate compounds. This can contribute to the development of new chemical processes or the synthesis of novel compounds with potential applications in various fields.
Used in Environmental Applications:
The ability of Glycine Bisphosphonate HBr to chelate metal ions can be exploited in environmental applications, such as the removal of heavy metals from contaminated water or soil. This can help in the development of more efficient and eco-friendly methods for environmental remediation.

Upstream product

• 949101-58-0 1-hydroxy-2-(N-phthaloylamino)ethane-1,1-diyl-bisphosphonic acid 
• 56-40-6 glycine 
• 201024-83-1 [1-(Dimethoxy-phosphoryl)-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-1-hydroxy-ethyl]-phosphonic acid dimethyl ester 

Relevant academic research and scientific papers

Dramatic enhancement in pH sensitivity and signal intensity through ligand modification of a dicobalt PARACEST probe

The employment of an ancillary amine-substituted bisphosphonate ligand affords a dicobalt complex able to quantitate pH with a remarkably high sensitivity of 8.8(5) pH unit?1 at 37 °C through a ratiometric paramagnetic chemical exchange saturation transfer (PARACEST) approach, where the different pH dependences of amine and amide CEST peak intensities are utilized.

Bisphosphonate complexation and calcium doping in silica xerogels as a combined strategy for local and controlled release of active platinum antitumor compounds

The production of bone substitute biomimetic materials which could also act as antitumoral drug release agents is of enormous interest. We report in this paper the synthesis and characterization of a novel platinum dinuclear complex containing a geminal bisphosphonate and its embodiment into xerogels prepared by the sol-gel method. Our goal was to obtain a hybrid inorganic matrix that could release a platinum species active against bone tumors or metastases, upon local implant. Two silica xerogels were considered: one was composed of pure silica, while the other contained also some calcium as potential release-modulating agent thanks to its high affinity for bisphophonates. The platinum-complex loading capacity of the inorganic matrices, the release kinetics in buffer simulating physiological conditions, and the stability upon storage were investigated as a function of Pt-complex concentration and calcium addition. We found that the presence of calcium in the composites deeply influences not only the stability of the formulations but also the nature of the platinum complex liberated in solution. The Royal Society of Chemistry.

Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis

Bisphosphonates such as zoledronic, alendronic and risedronic acids are a class of drugs clinically used to prevent bone density loss and osteoporosis. Novel P-C-P bisphosphonates were synthesized for targeting human farnesyl pyrophosphate synthase (hFPPS) and human geranylgeranyl pyrophosphate synthase (hGGPPS), key enzymes of the mevalonate pathway, and capable of anti-proliferative action on a number of cell lines (PC3, MG63, MC3T3, RAW 264.7, J774A.1, bone marrow cells and their co-colture with PC3) involved in bone homeostasis, bone formation and death. Among sixteen compounds, [1-hydroxy-2-(pyrimidin-2-ylamino)ethane-1,1-diyl]bis(phosphonic acid) (10) was effective in reducing PC3 and RAW 264.7 cell number in crystal-violet and cell-dehydrogenase activity assays at 100 μM concentration. 10 reduced differentiated osteoclasts number similarly with zoledronic acid in osteoclastogenesis assay. At nanomolar concentrations, 10 was more effective than zoledronic acid in inducing mineralization in MC3T3 and murine bone marrow cells. Further, 10 significantly inhibited the activity of hFPPS showing an IC50 of 0.31 μM and a remarkable hydroxyapatite binding of 90%. Docking calculations were performed identifying putative interactions between some representative novel bisphosphonates and both hFPPS and hGGPPS. Then, 10 was found to behave similarly or even better than zoledronic acid as a anti-resorptive agent.

Non-hydrolysable analogues of inorganic pyrophosphate as inhibitors of hepatitis C virus RNA-dependent RNA-polymerase

Inorganic pyrophosphate (PPi) is the product of the polymerization reaction catalyzed by DNA-and RNA-polymerases. A number of novel non-hydrolsable PPi analogues was synthesized; some of them inhibited the polymerization reaction catalyzed by hepatitis C virus RNA-dependent RNA-polymerase (NS5B). A new pharmacophore based on a non-hydrolysable methylenediphosphonate backbone has been developed. The structure-activity relationship analysis of 12 bisphosphonates is presented and the structural features crucial for NS5B polymerase activity inhibition are stated. Pleiades Publishing, Ltd., 2012.

A one-pot synthesis of 1-hydroxy-1,1-bis(phosphonic acid)s starting from the corresponding carboxylic acids

By starting with various carboxylic acids, a one-pot procedure for the synthesis of the corresponding 1-hydroxy-1,1-bis(phosphonic acid)s is reported. The efficiency of this simple methodology is illustrated by synthesizing well-known marketable amino hydroxy bis(phosphonate)s such as alendronate or N-methyl pamidronate without additional steps for the protection/deprotection of the amine function.

Therapeutic derivatives of diphosphonates

Novel chemotherapeutic agents having utility in treating infectious diseases such as periodontal disease, certain urinary tract infections, infectious urinary tract stones, and bone cancer, are obtained by combining chemically a diphosphonate compound with a therapeutic agent effective against the foregoing diseases.

The synthesis of 1-amino-2-hydroxy- and 2-amino-1-hydroxy-substituted ethylene-1,1-bisphosphonic acids and their N-methylated derivatives

A synthesis of 2-amino-1-hydroxyethylene-1,1-bisphosphonic acid 3 has been developed from N-phthaloylglycine via dimethyl 2-(N-phthaloylamino)acetylphosphonate 1. The preparation of the N-methylated and N,N-dimethylated derivatives 4 and 5 has been achieved by the reaction of 3 with formic acid and formaldehyde. The synthesis of 1-amino-2-hydroxyethylene-1,1-bisphosphonic acid 9 (R=R'=H) and its N-methylated and N,N-dimethylated analogues has been achieved by the reaction of phosphorus trichloride and phosphorous acid with the appropriate O-benzyl protected hydroxyacetamide, followed by catalytic hydrogenolysis of the protecting group.

Substituted ethane diphosphonic acids and salts and esters thereof

New and useful substituted ethane diphosphonic acids and salts thereof as exemplified by the compound having the formula EQU1 2-amino-1-hydroxyethane-1,1-diphosphonic acid and processes for preparing the same which generically comprise the "de-oxiranization" of an epoxy ethane diphosphonate having the formula EQU2 wherein R3 is hydrogen, a metal ion, or an organic radical.